<DOC>
	<DOCNO>NCT02871570</DOCNO>
	<brief_summary>The purpose study determine effect hepatic impairment rivipansel PK safety .</brief_summary>
	<brief_title>A Study Evaluate Effect IV Doses Rivipansel Subjects With Moderate Hepatic Impairment Healthy Subjects With Normal Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Female subject nonchildbearing potential male subject Body Mass Index ( BMI ) 17.5 40.0 kg/m2 Normal Hepatic function healthy subject Stable Hepatic Impairment subject moderate hepatic impairment Treatment investigational drug within 30 day dose study medication Pregnant female , breastfeed female subject male subject partner currently pregnant Use herbal supplement 28 day prior dose study medication Blood donation ( exclude plasma donation ) approximately 1 pint within 56 day prior study medication A positive urine drug screen illicit drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Rivipansel</keyword>
</DOC>